Clinical Analysis of 40 Multiple Myeloma Patients with Extramedullary Plasmacytoma of the Head

Overview

Journal J Int Med Res

Publisher Sage Publications

Specialty General Medicine

Date 2017 Mar 22

PMID 28322099

Citations 6

Authors

Wan-Jun Sun

Jia-Jia Zhang

Na An

Men Shen

Zhong-Xia Huang

Xin Li

Affiliations

Soon will be listed here.

Abstract

Objectives To investigate the clinical characteristics, survival and prognosis of patients with multiple myeloma (MM) and head extramedullary plasmacytoma (EMP). Methods Forty MM patients were enrolled in the study (18 men, 22 women; median age, 55 years). Results Median overall survival (OS) and progression-free survival (PFS) were 24 (5-78) months and 17 (2-36) months, respectively. The 2-, 3- and 5-year OS rates were 51%, 20% and 7%, respectively. The 2-year PFS was 15%. Median OS and PFS in patients administered velcade were 26 (18-50) and 22.5 (5-78) months, compared with 20 (10-30) and 13.5 (2-36) months in patients without velcade, respectively. Median OS was 23.5 (5-50) months in patients with EMP at MM diagnosis ( n = 25) and 36 (22-78) months in patients with head EMP diagnosed during the disease course ( n = 15). Sixteen MM patients had EMP invasion of the head only and 24 had invasion at multiple sites. Median OS was 25 (22-78) months in patients with EMP of the head only and 22 (5-78) months in patients with EMP invasion at multiple sites. Conclusion MM patients with head EMP show a more aggressive disease course and shorter OS and PFS. The prognosis of these patients is poor, especially in patients with head EMP at MM diagnosis, though combined chemotherapy and radiotherapy may prolong survival.

Citing Articles

Primary anaplastic extramedullary plasmacytoma in the lacrimal sac.

Gupta A, Abhaypal K, Chatterjee D, Kaur M, Singh M Digit J Ophthalmol. 2024; 30(3):60-63.

PMID: 39711988 PMC: 11658778. DOI: 10.5693/djo.02.2024.06.002.

Extramedullary Intracranial Plasmacytomas: A Systematic Review of Literature.

Palavani L, Bapat A, Batista S, Mendes J, Oliveira L, Bertani R Asian J Neurosurg. 2024; 19(2):137-144.

PMID: 38974431 PMC: 11226265. DOI: 10.1055/s-0044-1787535.

Potential Clinical Role of LncRNA miR503HG in Multiple Myeloma and its Effect on the Proliferation and Adhesion of Myeloma Cells.

Yin P, Zhou X Indian J Hematol Blood Transfus. 2024; 40(1):43-51.

PMID: 38312189 PMC: 10830954. DOI: 10.1007/s12288-023-01658-x.

Efficacy and Safety Analysis of VRD-PDCE in Treatment-Native Patients with Multiple Extramedullary Plasmacytomas or Plasma Cell Leukemia.

Zhao W, Chen L, Wang L, Wang W Indian J Hematol Blood Transfus. 2023; 39(3):383-391.

PMID: 37304491 PMC: 10247585. DOI: 10.1007/s12288-022-01610-5.

Extramedullary Plasmacytoma Causing Myelopathy Resulting in Gait Imbalance.

Wert J, Farooq A, Jalil A Cureus. 2021; 13(5):e15171.

PMID: 34168932 PMC: 8216312. DOI: 10.7759/cureus.15171.

References

. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003; 121(5):749-57. View

Rosenblum M, Bredeson C, Chang C, Rizzo J . Subcutaneous plasmacytomas with tropism to sites of previous trauma in a multiple myeloma patient treated with an autologous bone marrow transplant. Am J Hematol. 2003; 72(4):274-7. DOI: 10.1002/ajh.10296. View

Chen H, Wu T, Li Z, Shen H, Tang J, Fu W . Extramedullary plasmacytoma in the presence of multiple myeloma: clinical correlates and prognostic relevance. Onco Targets Ther. 2012; 5:329-34. PMC: 3496411. DOI: 10.2147/OTT.S35348. View

Lomeo P, McDonald J, Finneman J, Shoreline . Extramedullary plasmacytoma of the nasal sinus cavities. Am J Otolaryngol. 2006; 28(1):50-1. DOI: 10.1016/j.amjoto.2005.09.017. View

Chetty R, Bramdev A, Reddy A . Primary extramedullary plasmacytoma of the esophagus. Ann Diagn Pathol. 2003; 7(3):174-9. DOI: 10.1016/s1092-9134(03)00017-0. View

Weinstock M, Aljawai Y, Morgan E, Laubach J, Gannon M, Roccaro A . Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015; 169(6):851-8. PMC: 5944324. DOI: 10.1111/bjh.13383. View

Bold R . "Development of the proteasome inhibitor Velcade (Bortezomib)" by Julian Adams, Ph.D., and Michael Kauffman, M.D., Ph.D. Cancer Invest. 2004; 22(2):328-9. DOI: 10.1081/cnv-120030223. View

Deng S, Xu Y, An G, Sui W, Zou D, Zhao Y . Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases. Clin Lymphoma Myeloma Leuk. 2015; 15(5):286-91. DOI: 10.1016/j.clml.2014.12.013. View

Giuliani N, Caramatti C, Roti G, Geata A, Colla S, Bonomini S . Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes. J Clin Oncol. 2003; 21(9):1887-8. DOI: 10.1200/JCO.2003.05.177. View

10.

Schluterman K, Fassas A, Van Hemert R, Harik S . Multiple myeloma invasion of the central nervous system. Arch Neurol. 2004; 61(9):1423-9. DOI: 10.1001/archneur.61.9.1423. View

11.

Chen C, Masih-Khan E, Jiang H, Rabea A, Cserti-Gazdewich C, Jimenez-Zepeda V . Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents. Br J Haematol. 2013; 162(4):483-8. DOI: 10.1111/bjh.12414. View

12.

Petrucci M, Tirindelli M, De Muro M, Martini V, Levi A, Mandelli F . Extramedullary liver plasmacytoma a rare presentation. Leuk Lymphoma. 2003; 44(6):1075-6. DOI: 10.1080/1042819031000067882. View

13.

Huang S, Yao M, Tang J, Lee W, Tsay W, Cheng A . Epidemiology of multiple myeloma in Taiwan: increasing incidence for the past 25 years and higher prevalence of extramedullary myeloma in patients younger than 55 years. Cancer. 2007; 110(4):896-905. DOI: 10.1002/cncr.22850. View

14.

Oriol A . Multiple myeloma with extramedullary disease. Adv Ther. 2011; 28 Suppl 7:1-6. DOI: 10.1007/s12325-011-0079-0. View

15.

Damaj G, Mohty M, Vey N, DIncan E, Bouabdallah R, Faucher C . Features of extramedullary and extraosseous multiple myeloma: a report of 19 patients from a single center. Eur J Haematol. 2004; 73(6):402-6. DOI: 10.1111/j.1600-0609.2004.00331.x. View

16.

Gozzetti A, Cerase A, Lotti F, Rossi D, Palumbo A, Petrucci M . Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. Cancer. 2011; 118(6):1574-84. DOI: 10.1002/cncr.26447. View

17.

Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G . Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998; 102(5):1115-23. DOI: 10.1046/j.1365-2141.1998.00930.x. View

18.

Uppal H, Harrison P . Extramedullary plasmacytoma of the larynx presenting with upper airway obstruction in a patient with long-standing IgD myeloma. J Laryngol Otol. 2001; 115(9):745-6. DOI: 10.1258/0022215011908829. View

19.

Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M . Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2009; 21(2):325-330. DOI: 10.1093/annonc/mdp329. View

20.

Abdallah A, Atrash S, Shahid Z, Jameel M, Grazziutti M, Apewokin S . Patterns of central nervous system involvement in relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2013; 14(3):211-4. DOI: 10.1016/j.clml.2013.11.004. View